Universität zu Köln

Battista, Marco Johannes, Schmidt, Marcus ORCID: 0000-0003-1365-2414, Rieks, Nicole, Sicking, Isabel, Albrich, Stefan, Eichbaum, Michael, Koelbl, Heinz, Mallmann, Peter, Hoffmann, Gerald and Steiner, Eric (2015). Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. J. Cancer Res. Clin. Oncol., 141 (3). S. 555 - 563. NEW YORK: SPRINGER. ISSN 1432-1335

Full text not available from this repository.

Abstract

Purpose In 2013, 2009 and 2006, the Arbeitsgemeinschaft Gynaologische Onkologie evaluated the therapeutic approaches for endometrial carcinoma and the adherence to their guideline in Germany. Here, the adjuvant treatment decisions were presented. Methods A questionnaire was developed and sent to all 682 German gynecological departments in 2013 (775 in 2009 and 500 in 2006, respectively). The results of the questionnaires were compared with the recommendations of the guideline and with each other using Fisher's exact test. Results Responses were available in 40.0 % in 2013, 33.3 % in 2009 and 35.8 % in 2006. Participants recommended external beam radiotherapy (EBRT) in 13 out of 16 requested stages and vaginal brachytherapy (VBT) in only 10 out of 16 requested stages as suggested by the guideline. Comparing the results of 2013 with 2009, less participants used EBRT and VBT in 7 out of 16 and in 6 out of 16 requested stages, respectively. Conversely, more participants offered adjuvant chemotherapy (CT) in 2013 (90.4 %) compared to 61.9 % in 2009 (p < 0.001) and 48.8 % in 2006 (p < 0.001), respectively. However, the stage-adjusted recommendations of CT were not in line with the guideline in 11 out of 15 requested stages. In total, 77.3 % of the participants use a multiple drug schedule with a platinum and a taxane compound. Conclusions The results suggest non-adherence to the guideline concerning the stage-adjusted use of VBT and CT in endometrial carcinoma. These findings emphasize great uncertainties and the need of more clarifying trials. Furthermore, a shift from radiotherapy toward CT is observable.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Battista, Marco Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidt, Marcus UNSPECIFIED orcid.org/0000-0003-1365-2414 UNSPECIFIED Rieks, Nicole UNSPECIFIED UNSPECIFIED UNSPECIFIED Sicking, Isabel UNSPECIFIED UNSPECIFIED UNSPECIFIED Albrich, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichbaum, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Koelbl, Heinz UNSPECIFIED UNSPECIFIED UNSPECIFIED Mallmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Gerald UNSPECIFIED UNSPECIFIED UNSPECIFIED Steiner, Eric UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-406915
DOI:	10.1007/s00432-014-1834-9
Journal or Publication Title:	J. Cancer Res. Clin. Oncol.
Volume:	141
Number:	3
Page Range:	S. 555 - 563
Date:	2015
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-1335
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PHASE-III TRIAL; EXTERNAL-BEAM RADIOTHERAPY; RADIATION-THERAPY; INTERMEDIATE-RISK; VAGINAL BRACHYTHERAPY; PELVIC RADIOTHERAPY; STAGE-II; CARCINOMA; CHEMOTHERAPY; IRRADIATION Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/40691